USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes

Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease

USFDA accepts biologics license application for GC Biopharma's GC5107B

InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China

Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData

Approval to dramatically change CAR-T therapies landscape

Annovis’ Buntanetap in PD faces complex road ahead despite phase III progress, says GlobalData

The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023

ENPICOM secures extended financing from current investors

Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma

Baghel inaugurates the World Blood Donor Day at RML Hospital

The slogan for this year's World Blood Donor Day campaign is 'Give blood, give plasma, share life, share often'